sFlt-1 Activators
Chemical activators of the protein sFlt-1 can influence its activity through various mechanisms, predominantly by modulating the intracellular levels of cyclic AMP (cAMP) and the subsequent activation of protein kinase A (PKA). Forskolin directly stimulates adenylyl cyclase, the enzyme responsible for converting ATP to cAMP. Elevated levels of cAMP can activate PKA, which in turn may phosphorylate sFlt-1, leading to its activation. Similarly, Isoproterenol and Epinephrine, by binding to beta-adrenergic receptors, activate adenylyl cyclase, thus increasing cAMP and activating PKA. This cascade is not exclusive to these compounds; other chemicals such as Dopamine and Salbutamol also target beta-adrenergic receptors to elevate cAMP and activate PKA, which again can phosphorylate sFlt-1. Terbutaline utilizes a comparable pathway by engaging beta-2 adrenergic receptors to increase cAMP and thereby activate PKA, which can phosphorylate and activate sFlt-1.
Moreover, Prostaglandin E2 (PGE2) interacts with its own set of G protein-coupled receptors, leading to increased cAMP and PKA activation. Histamine, by engaging H2 receptors, similarly results in cAMP accumulation and PKA activation, with possible downstream effects on sFlt-1. Additionally, certain chemicals function by inhibiting the breakdown of cAMP, thus sustaining its cellular levels and the activation state of PKA. IBMX, a non-selective inhibitor of phosphodiesterases, prevents cAMP degradation, as does Anagrelide, though it is more selective in its inhibition. Rolipram, targeting phosphodiesterase 4 (PDE4), and Cilostamide, targeting phosphodiesterase 3 (PDE3), both lead to increased cAMP levels and enhanced PKA activation. Such sustained activation of PKA can result in the phosphorylation of various proteins, including sFlt-1. Through these diverse yet interconnected pathways, the chemical activators effectively modulate the activity of sFlt-1 within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol binds to and activates beta-adrenergic receptors, which can stimulate adenylyl cyclase activity, thereby raising intracellular cAMP levels and activating PKA, ultimately enhancing phosphorylation and activation of sFlt-1. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine, through its interaction with beta-adrenergic receptors, increases cAMP production via adenylyl cyclase activation. The resulting PKA activation can lead to phosphorylation of downstream targets, potentially including sFlt-1. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 interacts with its G protein-coupled receptors (EP receptors), which can increase intracellular cAMP levels, leading to PKA activation. PKA can then phosphorylate various proteins, possibly leading to sFlt-1 activation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, enzymes that break down cAMP. By inhibiting these enzymes, IBMX can raise cAMP levels, leading to PKA activation and subsequent phosphorylation of proteins, potentially sFlt-1. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine can bind to H2 receptors, which activate adenylyl cyclase, increasing cAMP levels. The elevated cAMP can lead to PKA activation, which may result in phosphorylation and activation of proteins such as sFlt-1. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine, through its D1-like receptors, can stimulate adenylyl cyclase, increasing cAMP concentration and leading to PKA activation. PKA-mediated phosphorylation cascades could then lead to the activation of sFlt-1. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide increases cAMP levels by inhibiting phosphodiesterases. The increased cAMP levels activate PKA, which can phosphorylate and potentially activate sFlt-1. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram selectively inhibits phosphodiesterase 4 (PDE4), leading to an increase in cAMP levels in cells. This increase can promote PKA activation, which may lead to the phosphorylation and activation of sFlt-1. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $94.00 $141.00 | ||
Salbutamol binds to beta-2 adrenergic receptors, stimulating adenylyl cyclase and increasing cAMP levels. This increase can activate PKA, which has the potential to phosphorylate and activate sFlt-1. | ||||||
Terbutaline Hemisulfate | 23031-32-5 | sc-204911 sc-204911A | 1 g 5 g | $92.00 $378.00 | 2 | |
Terbutaline, a beta-2 adrenergic agonist, can raise intracellular cAMP levels by activating adenylyl cyclase. The resulting PKA activation may lead to phosphorylation events that activate sFlt-1. | ||||||